Results for Wildtype differ from all those for Vector (GI50(Wildtype)/GI50(Vector)= 1 . 5; P < 0. 01), indicating that transfection with an empty construct changes the fenretinide sensitivity of the cells; CRABP1 cells differ from Vector cells (GI50(CRABP1)/GI50(Vector)= 0. 8; P < 0. 01) at 4 and 8M fenretinide. manipulation of p75NTR expression on CRABP1 expression and the effects of CRABP1 expression on fenretinide efficacy are therefore neuroblastoma cell line-dependent. Basimglurant Potentiation from the antineuroblastoma cell effects of fenretinide by p75NTR is not mediated solely through CRABP1. == 1 . Introduction == The p75 neurotrophin receptor (p75NTR) continues to be implicated in both development and disease and, in its interactions with its cognate ligands and binding partners, regulates cell fate [1]. The signaling pathways transduced by p75NTR are complex and each can lead to several alternative downstream results dependent on cell type and environment. The p75NTR is a transmembrane cell surface receptor, the intracellular domain (p75ICD) of which Keratin 18 antibody is cleaved off and functions as a transcription factor to modulate protein expression. Parkhurst et al. [2] have shown that p75ICD can translocate to the nucleus, associate with all the cyclin E1 promoter, and increase mRNA levels of cyclin E1 in PC12 and HEK293 cells. We have previously demonstrated that p75NTR affects cellular response to oxidative stress [3] and upregulates the enzymes that mediate cholesterol biosynthesis [4]. More recently, it was demonstrated that knocking down p75NTR expression in neuroblastoma cell lines attenuates the cellular response to the chemotherapeutic drug, fenretinide, while p75NTR overexpression has the opposite effect [5]. However , the mechanisms that underlie the potentiation of the Basimglurant effects of fenretinide by p75NTR are incompletely comprehended. Neuroblastoma is the most common extracranial solid tumor of childhood. It derives from the neural crest and commonly reveals clinically in the adrenal gland or sympathetic chain. Fenretinide, a retinoic acid derivative, is under active clinical investigation intended for the treatment of neuroblastoma. Unlike all-trans retinoic acidity Basimglurant (ATRA), which is used to induce cellular differentiation in the treatment of cancer, fenretinide is known to cause apoptosis through generation of mitochondrial reactive oxygen species thought to leak from Complex II [5, 6] and differs structurally from ATRA by only a hydroxyphenyl group. In a recent phase II trial of 65 patients, fenretinide did not meet criteria intended for clinical efficacy [7] due to low bioavailability of the drug. However , there are now ongoing phase I clinical trials for a new formulation [8] as well as other drug delivery systems developing in the pipeline [9]. Our previous studies [5, 10] examined the dependence of fenretinide efficacy on components of the p75NTR proapoptotic signaling pathways and exhibited enhancement of those pathways and attenuation of antiapoptotic pathways in the presence of p75NTR expression. A microarray study has recognized CRABP1 as one of the 52 cancer-related genes of which p75NTR alters the expression [11]. The presently explained studies test the hypothesis that p75NTR-induced potentiation from the effects of fenretinide on neuroblastoma cells occurs through regulation by p75NTR of the expression of the cellular retinoic acidity binding protein I (CRABP1). The studies of others suggest that CRABP1 enhances conversion of fenretinide to its more potent metabolite, 4-oxo-fenretinide [12]. If this is true in neuroblastoma cells, this enhanced metabolism of fenretinide to 4-oxo-fenretinide could enhance the antineuroblastoma efficacy of fenretinide. Although little is known about CRABP1, it is implicated in regulating retinoid metabolism, rendering retinoids unavailable to nuclear receptors Basimglurant [13], and increasing intracellular concentrations of their active metabolites [14]. == 2 . Methods == == 2 . 1 . Cell Lines and Reagents == IMR-32, SH-SY5Y, SH-EP1, and SK-N-AS human being neuroblastoma cells were obtained from the American Type Culture Collection (Rockville, MD). SH-EP1 cells were transfected to effect overexpression (p75OE cells) or mock transfected (OE Ctrl) as we have previously explained [5, 10, 15]. == 2 . 2 . Knockdown of p75NTR == p75NTR was knocked down in p75OE cells with siRNA [5] using Lipofectamine 2000 according to the manufacturer’s instructions (Life Technologies, Chicago, IL). In addition , stable knockdown of p75NTR in SH-EP1 cells in their native state was performed by lentiviral transduction as we have previously explained [5] using shRNA. The sequences of shRNA against p75NTR are NC-1, GAGGATCGGAGGCTTGTCA; NC-2, GGACAGAGTCTGGGTGTATTTATTT. == 2 . 3. Knockdown of CRABP1 == Transient knockdown of CRABP1 was performed by nucleofection with a Nucleofector Kit V and the corresponding programs.